Tagged with EY

Turkey Ingrid Drechsel, head of Bayer’s pharma operations in Turkey and Iran, discusses the complexity of managing two countries under economic pressure and the advantages of Bayer’s longstanding relationship in both markets with a track record of six decades. In addition, Drechsel explains how the German company has moved from fifth…

Turkey Menarini’s general manager for Turkey, the Middle East and Africa Uğur Bingöl discusses the Italian company’s restructuring in the region and its desire to replicate its success in Turkey across MEA. Moreover, he comments on the future of antibiotics as the scientific community warns about antimicrobial resistance, the pandemic’s impact…

Turkey The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D expenditure and Turkey’s big opportunity ahead in biosimilars production. In addition, Malkoç discusses the persisting issues within the country’s pricing and reimbursement system and why localization policies have been a net gain for…

Turkey Janssen’s Managing Director for Turkey, Demet Russ, discusses her return to the country after 25 years abroad, having worked for Johnson & Johnson in different local, regional and global roles in Germany, Belgium, France and the US. She explains how Janssen Turkey’s vision “We are here for the better” is…

Turkey According to a recent report by IEIS, Turkey’s Pharmaceutical Manufacturers Association, there are approximately 680 companies competing in the country’s pharmaceutical industry. Together, they operate 96 pharmaceutical and 11 raw material production facilities. The industry employs over 40,000 people, exports to 180 countries, and produces more than 12 thousand products.…

Turkey As one of the leading pharma companies in Turkey, DEVA is pioneering a new approach to generics in the country. Chairman of the Board and CEO Philipp Haas discusses the company’s presence and strategy in international markets, how the firm is leveraging its three US FDA-approved and EU GMP-certified production…

Turkey As COVID-19 began spreading through the world, the race to understand the disease by scientists and doctors took off. After just a few months, it became apparent that people with diabetes seemed to suffer more severe effects; 50 percent of people diagnosed with COVID-19 also suffered from diabetes. As a…

Turkey Istanbul’s First Instance IP Court recently dismissed a negative declaratory action (the “Case”) against our client citing the plaintiff’s lack of standing because the pharmaceutical at issue was unlicensed as of the when the action was started. The ruling is noteworthy because it appears to confirm the precedential force of…

Turkey The president of the Turkish Society of Cardiology, Mustafa Kemal Erol, discusses the prevalence of cardiovascular disease, which accounts for over a third of deaths in Turkey, the improvements made after the 2008 smoking ban, and their work with the healthcare industry and academia to raise awareness and bring the…

Turkey AmCham Turkey’s executive director, Asli Özelli, examines the impact of US companies on the Turkish economy with over USD 50 billion in investment, their help during the pandemic, the chamber’s efforts to develop local talent and take advantage of the country’s advanced healthcare infrastructure to promote medical tourism, and explains…

Turkey Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials, localization and an operational hub overseeing 75 countries. After almost two decades working with the Danish diabetes and obesity giant,…

Turkey Turkey’s former Minister of Health, Bülent Akarcali, outlines the country’s healthcare system evolution over the past decades, comparing the improvements to the difference between a Ford Model T to a Tesla. In addition, he explains why medical tourism is and will continue to be a big business opportunity for Turkey…